Humanized antibodies against the beta-amyloid peptide

ABSTRACT

The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.

The present application is a divisional application of U.S. patentapplication Ser. No. 12/677,732 filed Jun. 9, 2010, a national stageapplication of PCT/CH2008/000382 filed Sep. 15, 2008, which claims thebenefit under 35 USC 119(e) of U.S. Patent Application No. 61/083,698filed Jul. 25, 2008, and 60/993,612 filed Sep. 13, 2007. The entirecontents of each of the above documents are incorporated herein byreference.

TECHNICAL FIELD

The present invention relates to the field of antibody technology, morespecifically to the field of humanized antibodies against thebeta-amyloid peptide.

BACKGROUND ART

Alzheimers disease (AD) is an age-related neurodegenerative disorder,which affected in 2006 26 6 million people. Forecasts predict that theprevalence will quadruple by 2050, by which time 1 in 85 personsworldwide will be living with the disease (Brookmeyer et al. (2007)). ADmanifests itself as progressive cognitive deficits, such as memory lossand a decline in mental abilities.

Central in the pathogenesis of AD is the accumulation of beta-amyloidpeptide (Abeta) in the brain. Abeta is a cleavage product of the amyloidprecursor protein (APP) which is sequentially cleaved in theamyloidogenic pathway, first by B-secretase and then by γ-secretase. Theresulting Abeta fragments are of variable size, whereas the 40 aminoacid peptide (Abeta₄₀) is the most abundant species and the 42 aminoacid peptide, the so-called Abeta₄₂, is believed to be the most harmfulspecies. Abeta can accumulate in the extracellular space of the brain,where it aggregates in a multistep process to form neurotoxic oligomeresand finally gives rise together with other substances to amyloidplaques, which are a typical hallmark of the Alzheimer disease.

A promising clinical immunologic approach for the treatment ofAlzheimer's disease is passive immunization, in which antibodies againstAbeta are administered to the subject in order to remove Abeta from thebrain. Three different mechanisms for Abeta clearance through anti-Abetaantibodies have been proposed, which are not mutually exclusive: (1) thecatalytic conversion of fibrillar Abeta to less toxic forms (Bard et al.(2000); Bacskai et al. (2001); Frenkel et al. (2000)); (2) theopsonization of Abeta deposits, leading to microglial phagocytosis (Bardet al. (2000); Bacskai et al. (2002); Frenkel et al. (2000); and (3) thepromotion of the efflux of Abeta from the brain to the circulation(DeMattos et al. (2001)), the so-called peripheral sink hypothesis.

Mohajera et al. (2004) and Gaugler et al. (2005) of the University ofZurich have generated mouse antibodies against Abeta and studied thebioactivity of monoclonal murine anti-Abeta antibodies in vivo.

However, murine antibodies often result in immunogenicity whenadministrated to human beings. The elicited anti-globulin responselimits the clinical utility of murine antibodies (Miller et al. (1983);Schroff et al. (1985)).

Hence, there is a need for new, non-immunogenic and effective antibodiesfor the treatment and/or diagnosis of Abeta-related disorders,specifically of Alzheimer's disease.

DISCLOSURE OF THE INVENTION

Hence, it is a general object of the invention to provide an antibodywhich specifically binds to Abeta, in particular to the C-terminal partof Abeta, and which is well tolerated by the human immune system.

In a first aspect, the invention provides an isolated antibody thatselectively binds to Abeta in its C-terminal region, in particularbetween amino acids 30 to 40 (SEQ. ID. No. 26) and is humanized or fullyhuman. The antibody displays a high affinity for both Abeta42 andAbeta40 and furthermore, does not substantially recognize amyloidprecursor protein (APP) in vivo.

The advantage of the so-called humanized antibodies consists in theirability to elicit typically minimal or no response of the human immunesystem thus can be considered as being low or non-immunogenic upon humanapplication. Therefore, contrary to murine antibodies, humanizedantibodies are suitable for therapeutic purposes and clinicalapplication.

The term “humanization” refers to well-established techniques whichreduce the immunogenicity of xenogeneic antibodies. A humanized antibodyis genetically engineered so that as little as possible non-humanstructure is present. One strategy is based on the grafting ofcomplementarity determining regions (CDRs) of a xenogeneic antibody ontothe variable light chain VL and variable heavy chain VH of a humanacceptor framework. In another strategy, the framework of a xenogeneicantibody is mutated towards a human framework. In both cases, theretention of the functionality of the antigen-binding portions isessential. For said purpose, the three dimensional models of theparental sequences and various conceptual humanized products areanalyzed, e.g. by the use of computer programs for molecular modellingwhich are well known to the skilled person. The analysis permits—amongother—to identify the framework residues likely to be involved directlyor indirectly in antigen binding. Often, a small number of donorframework residues are important for antigen binding because they enterin direct contact with the antigen or they affect the conformation ofparticular CDRs (Davies et al (1990); Chothia et al (1987)). Hence, ifnot already present, it is desirable to mutate the correspondingacceptor framework residues towards those donor framework residues whichhave been identified as being important for antigen binding. It may alsobe possible that humanized antibodies comprise residues which are foundneither in the human germline repertoire in vivo, nor in the donor CDRsor even in the donor framework.

The degree of humanization of an antibody may be indicated bycalculating the percentage of sequence identity of the framework of thehumanized antibody to the original human acceptor framework that wasused to generate the humanized antibody and that is obtainable from ahuman library. Preferably, the antibody of the invention comprises aframework with at least 60% identity, more preferably (in the followingorder) at least 75%, at least 80%, at least 85%, at least 90%, and mostpreferably 95% or even 100% identity to a framework obtainable of ahuman library. In the context of the present invention, the terms“complementarity determining regions” or “CDRs” refer to thecomplementarity determining regions of an antibody which consist of theantigen binding loops as defined by Kabat et al. (1991). CDR andframework residues of the present invention are determined according tothe definition of Kabat (Kabat et al. (1987).

The term “antibody” as used herein refers to full-length antibodies,being for example monoclonal antibodies, and any antigen-bindingfragment or single chain thereof with sufficient binding capacity forthe selected antigen. Examples of antigen-binding fragments encompassedby the present invention include Fab fragments, F(ab′)2 fragments, Fdfragments, Fv fragments; single domains or dAb fragments, isolatedcomplementarity determining regions (CDR); a combination of two or moreisolated CDRs which may optionally be joined by a synthetic linker andsingle chain variable fragments (scFv). “Full-length antibodies” includechimeric antibodies, in which an antigen-binding variable domain of oneorigin is coupled to a constant domain of a different origin, e.g. thevariable domain Fv of a murine antibody to the constant domain Fc of ahuman antibody.

The above enumerated antibody fragments are obtained using conventionaltechniques known to those with skill in the art, and the fragments arescreened for utility in the same manner as are intact antibodies.

In the present invention, the CDRs are derived from the monoclonal mouseantibody 22C4 (Mohajeri et al. (2002), J. Biol. Chem. 277, pp.33012-33017 and Neurodegenerative Dis. 1 (2004), pp. 160-167). Saidmurine antibody is directed against the C-terminal part of Abeta, morespecifically to an epitope within amino acids 30 to 40 (SEQ. ID. No.26).

In a preferred embodiment, the antibody prevents the oligomerization ofAbeta, particularly of Abeta₄₀ and/or Abeta₄₂, through binding to itstarget.

The present invention provides an antibody that comprises one or morecomplementarity determining regions (CDR) sequences with at least 80%identity to a sequence of the group consisting of SEQ ID: No. 1, SEQ ID:No. 2, SEQ ID: No. 3, SEQ ID: No. 4, SEQ ID: No. 5 and SEQ ID: No. 6.

As already mentioned, the CDRs of the present invention, namely SEQ ID:No. 1, SEQ ID: No. 2, SEQ. ID: No. 3, SEQ ID: No. 4, SEQ ID: No. 5 andSEQ ID: No. 6, can be grafted into suitable acceptor frameworks. Theterm “frameworks” refers to the art recognized portions of an antibodyvariable region that exist between the more divergent CDR regions. Suchframework regions are typically referred to as frameworks 1 through 4(FR1, FR2, FR3, and FR4) and provide a scaffold for holding, inthree-dimensional space, the three CDRs found in a heavy or light chainantibody variable region, such that the CDRs can form an antigen-bindingsurface. Suitable acceptor frameworks are preferably those ofimmunoglobulin-derived antigen-binding polypeptides which are well-knownin the art and include, but are not limited to VhH domains, V-NARdomains, Vh domains, Fab, scFv, Bis-scFv, Camel IG, IfNAR, IgG, Fab2,Fab3, minibody, diabodies, triabodies and tetrabodies (see Holliger, P.and Hudson, P. (2005), Nat. Biotechnol. 23(9), pp. 1126-1136). Theframework sequence may also be a consensus sequence of a human frameworksequence.

The antibody is selected from any class of immunoglobulins, includingIgM, IgG, IgD, IgA and IgE, and isotype, and may comprise sequences formore than one class or isotype.

Preferably, the antibody comprises a framework with at least 60%identity, more preferably (in the following order) at least 75%, atleast 80%, at least 85%, at least 90%, and most preferably 95% or even100% identity to a framework obtainable of a human library.

The antibody of the present invention is a recombinant molecule, sincethe CDRs can be grafted upon a human framework and the resultingantibody comprises non-human CDRs and a human or essentially humanframework. Alternatively, the antibody is derived form a non-humanantibody and its framework is mutated towards a human antibody. Bothalternatives are encompassed by the term “obtainable of a humanlibrary”.

In one embodiment of the present invention, the antibody is a scFvantibody. The scFv can be either a full-length scFv comprising a VL anda VH domain which are linked by a short linker peptide, for example alinker comprising 1 to 4 repeats of the sequence GGGGS, preferably a(GGGGS)₄ peptide (SEQ ID No. 25), or a linker as disclosed in Alfthan etal. (1995) Protein Eng. 8:725-731, or simply a VL or a VH domain, whichhas sufficient binding capacity for the selected antigen. The linkage ofVL and VH can be in either orientation, VL-linker-VH or VH-linker-VL.

In one embodiment, the framework of the scFv is stable and soluble in areducing environment. These characteristics can be identified by theso-called Quality control system, as disclosed in WO01/48017. Thestability of said antibodies preferably is at least half as good as thestability of the particularly stable lambda graft, more preferably atleast as good as the lambda graft, and most preferably better than thelambda graft. Worn et al. (2000) describe the onset of denaturation ofthe lambda graft to be around 2.0M GdnHCl. It has been shown that scFvswhich perform well in the Quality control system are also stable andsoluble under oxidizing conditions. In a preferred embodiment, thesolubility of the antibody of the invention as measured according to themethod of Atha and Ingham (1981) is at least 5 mg/ml, more preferably atleast 10 mg/ml, and most preferably at least 20 mg/ml.

In a further preferred embodiment, the antibody comprises a variablelight chain fragment (V_(L)) framework which is identical or derivedfrom the framework sequences comprised in the sequences of the groupconsisting of SEQ ID. No. 7, SEQ ID. No. 8, SEQ ID. No. 10, SEQ ID. No.11, SEQ ID. No. 12, SEQ ID. No. 13, SEQ ID. No. 14, SEQ ID. No. 15 andSEQ ID. No. 16. In case of a derived sequence, said sequence shows atleast 60% identity, more preferably (in the following order) at least75%, at least 80%, at least 85%, at least 90%, and most preferably 95%or even 100% identity to a sequence of the group consisting of SEQ ID.No. 7, SEQ ID. No. 8, SEQ ID. No. 10, SEQ ID. No. 11, SEQ ID. No. 12,SEQ ID. No. 13, SEQ ID. No. 14, SEQ ID. No. 15 and SEQ ID. No. 16.

In a further preferred embodiment, the antibody of the present inventioncomprises a variable heavy chain fragment (V_(H)) framework which isidentical or derived from the framework sequences comprised in thesequences of the group consisting of SEQ ID. No. 17, SEQ ID. No. 18, SEQID. No. 20, SEQ ID. No. 21, SEQ ID. No. 22 and SEQ ID. No. 23. In caseof a derived sequence, said sequence shows at least 60% identity, morepreferably (in the following order) at least 75%, at least 80%, at least85%, at least 90%, and most preferably 95% or even 100% identity to asequence of the group consisting of SEQ ID. No. 17, SEQ ID. No. 18, SEQID. No. 20, SEQ ID. No. 21, SEQ ID. No. 22 and SEQ ID. No. 23.

Sequences SEQ ID. No. 8, SEQ ID. No. 10, SEQ ID. No. 11, SEQ ID. No. 12,SEQ ID. No. 13, SEQ ID. No. 14, SEQ ID. No. 15 SEQ ID. No. 16, SEQ ID.No. 20, SEQ ID. No. 21, SEQ ID. No. 22 and SEQ ID. No. 23 are disclosedin WO03/097697. These framework sequences stem from human immunoglobulinorigin and their solubility and stability characteristics under reducingconditions have been proven in the so-called Quality control system, asdisclosed in WO01/48017.

More preferably, the antibody comprises a VH fragment of SEQ ID: No. 7and a VL sequence of SEQ ID: No. 17.

Most preferably, the antibody has a sequence being at least 60%identical, more preferably at least 75%, 80%, 90%, 95% identical to Seq.ID. No. 24. In a most preferred embodiment, the antibody of the presentinvention is structurally defined by Seq. ID. No. 24. In said antibody,SEQ ID: No. 7 and SEQ ID: No. 17 are linked through a (GGGGS)₄ linker.The resulting scFv antibody was named ESBA212.

It will be understood by one of ordinary skill in the art that thesequences of the invention may be altered such that they vary in aminoacid sequence from the here disclosed sequences, while retaining theselective binding ability to the C-terminal part of Abeta. Hence,neither the framework nor the CDR regions of the humanized antibody needto correspond precisely to the donor CDR or acceptor framework.Alterations therein can be created by introducing one or more nucleotidesubstitutions, additions or deletions into the nucleotide sequence ofthe antibody by standard techniques, such as site-directed mutagenesisand PCR-mediated mutagenesis. Such mutations can be introduced fordifferent purposes, e.g. for improving binding, solubility or stabilitycharacteristics of the antibody. The antibodies of the invention mayalso comprise conservative amino acid substitutions at one or morenon-essential amino acid residues. In another embodiment, mutations maybe introduced randomly along all or part of the coding sequence such asby saturation mutagenesis, and the resultant mutants can be screened fortheir ability to bind to the desired target.

The percent identity between two sequences is a function of the numberof identical positions shared by the sequences, taking into account thenumber of gaps, and the length of each gap, which need to be introducedfor optimal alignment of the two sequences. The comparison of sequencesand determination of percent identity between two sequences can beaccomplished using a mathematical algorithm, which is well known tothose skilled in the art. The identities referred to herein are to bedetermined by using the BLAST programs (Basic Local Alignment SearchTools; see Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman,D. J. (1990) “Basic local alignment search tool.” J. Mol. Biol.215:403-410) accessible in Internet. BLAST protein searches can beperformed with the XBLAST program, score=50, wordlength=3 to compareamino acid sequences to the protein molecules of the invention. Toobtain gapped alignments for comparison purposes, Gapped BLAST can beutilized as described in Altschul et al., (1997) Nucleic Acids Res.25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, thedefault parameters of the respective programs (e.g., XBLAST and NBLAST)can be used.

The protein sequences of the present invention can further be used as a“query sequence” to perform a search against public databases to, forexample, identify related sequences. Such searches can be performedusing the aforementioned XBLAST programs (version 2.0).

The humanized or fully human antibodies encompassed by the presentinvention show the following characteristics:

(i) Binding to the C-terminus of Abeta, thus binding to both Abeta40 andAbeta42 with a high and substantially identical affinity;

(ii) Displaying a high affinity for oligomeric and monomeric forms ofAbeta;

(iii) Not substantially recognizing amyloid precursor protein (APP) invivo;

(iv) Having a solubility of at least 5 mg/ml, preferably at least 10mg/ml, and more preferably at least 20 mg/ml; and

(v) Showing low or no immunogenicity upon human application.

Further, the antibody preferably shows at least one, more preferablymore than one, most preferred all of the following characteristics:

(vi) Mediating the uptake of fibrillar Abeta by microglia;

(vi) Binding beta-amyloid plaques;

(vii) Removing beta-amyloid plaques in the brain and/or preventing theformation of amyloid plaques in the brain;

(viii) Decreasing Abeta toxicity and associated vulnerability of neuronsto excitotoxic events produced by seizures;

(ix) Crossing the blood brain barrier; and/or

(x) Substantially restoring normal behavior;

(xi) Removing beta-amyloid fibrils in the brain and/or preventing theformation of amyloid fibrils in the brain.

The antibody of the present invention does not substantially recognizeamyloid precursor protein (APP) in vivo. Preferably, the bindingaffinity to Abeta is a factor of at least two, more preferably at least5, even more preferably at least 10, particularly preferably at least50, and most preferably at least 100 times higher when compared to thebinding affinity for APP.

Thus, upon administration of the antibody to a subject, APP does notcompete with Abeta for binding and the antibody does not interfere withthe biology of uncleaved APP. This feature is e.g. particularlyinteresting for diagnostic purposes and/or medical treatment ofneurological disorders associated with abnormal accumulation and/ordeposition of Abeta in the central nervous system.

The term “neurological disorder” as used herein includes—but is notlimited to—Alzheimer's disease, mild cognitive impairment, aphasia,fronto-temporal dementia, Lewy-body disease, Parkinson's disease, Pick'sdisease, Binswanger's disease, cerebral amyloid angiopathy, Down'ssyndrome, multi-infarct dementia, Huntington's Disease,Creutzfeldt-Jakob Disease, AIDS dementia complex, depression, anxietydisorder, phobia, Bell's Palsy, epilepsy, encephalitis, multiplesclerosis; neuromuscular disorders, neurooncological disorders, braintumors, neurovascular disorders including stroke, neuroimmunologicaldisorders, neurootological disease, neurotrauma including spinal cordinjury, pain including neuropathic pain, pediatric neurological andneuropsychiatric disorders, sleep disorders, Tourette syndrome, mildcognitive impairment, vascular dementia, multi-infarct dementia, cysticfibrosis, Gaucher's disease other movement disorders, glaucoma anddisease of the central nervous system (CNS) in general. More preferably,the antibody of the present invention is used in the treatment,prevention, delay of progression or diagnosis of Alzheimer's disease,stroke, neurotrauma and glaucoma.

In another aspect the antibody of the present invention is chemicallymodified. Chemical modifications may change properties of the antibodysuch as stability, solubility, antigen-binding specificity or affinity,in vivo half life cytotoxicity, and tissue penetration ability. Chemicalmodifications are well known to the skilled person. A preferred chemicalmodification of the antibody of the present invention is PEGylation.

In one embodiment, the antibody is conjugated to a therapeutic agent,e.g. a toxin or a chemotherapeutic compound. The antibody may beconjugated to a radioisotope, such as—without being limited to—²¹²Bi,¹²⁵I, ¹³¹I, ⁹⁰Y, ⁶⁷Cu, ²¹²Bi, ²¹²At, ²¹¹Pb, ⁴⁷Sc, ¹⁰⁹Pd, and ¹⁸⁸Re, e.g.for immunotherapy.

In a further embodiment, the antibody of the present invention may belinked to a label. Said label may allow for colorimetric detection ofthe antibody. Alternatively, the antibody is radiolabelled. Mostpreferably, the radiolabel is ⁶⁴Cu.

Another object of the present invention is to provide a diagnostic orscientific tool comprising the antibody disclosed herein.

The antibody of the present invention may be used in diagnosis orscreening a subject for amyloidosis or Alzheimer's disease ordetermining a subject's risk for developing amyloidosis or Alzheimer'sdisease.

In a further embodiment, the invention furthermore encompasses adiagnostic method comprising the step of administering an effectiveamount of an antibody of the present invention to a subject, preferablya mammal. The method further comprises the 30 step of detecting thelabel.

In a further embodiment, the present invention encompasses animmunoassay comprising the antibody described herein, wherein the assaymay be an in vivo or an in vitro immunoassay. The antibody may be usedin liquid phase or bound to a solid phase. Examples of such immunoassaysinclude radioimmunoassays (RIA), flow cytometry, Western Blots andmicroarrays.

Furthermore, the invention encompasses a test kit comprising theantibody disclosed herein.

In a preferred embodiment, the antibody of the present inventionmediates the uptake of fibrillar Abeta by microglia, thereby reducingAbeta levels in vivo.

In a further preferred embodiment, the antibody of the present inventionimproves upon administration of an effective amount the cognitivebehavior and rescues the number of immature neurons in subjects withAlzheimer's disease.

Moreover, the present invention encompasses a a pharmaceuticalcomposition to treat, prevent and/or delay the progression of aneurological disorder or amyloidosis characterized by abnormalaccumulation and/or deposition of Abeta in the central nervous system,in particular Alzheimer's disease, comprising the antibody disclosedherein.

In a further embodiment, the invention provides a method of manufactureof a pharmaceutical composition for the treatment, prevention, and/ordelay of progression of the above mentioned neurological disorders,preferably Alzheimer's disease, comprising the step of combining theantibody disclosed herein with at least one suitable pharmaceuticalcarrier.

Preferably, the pharmaceutical compositions disclosed herein preventand/or reduce the effect of Abeta accumulation in the brain of asubject.

The antibody can be administered in combination with a pharmaceuticallyacceptable carrier or in combination with one or more further effectiveagents. Effective agents may be small organic molecules and/oranti-Abeta antibodies.

The antibody and/or pharmaceutical compositions disclosed herein may beadministered in different ways, e.g. intravenously, intraperitoneally,intranasally, subcutaneously, intramuscularly, topically orintradermally, intracranially, intrathecally into the cerebrospinalfluid. Preferred kinds of application are (in this sequence) intranasal,subcutaneous, intravenous, intrathecally into the cerebrospinal fluidand intracranial administration.

Typically used formulations are known to the skilled person. Forexample, aerosol formulations such as nasal spray formulations includepurified aqueous or other solutions of the active agent withpreservative agents and isotonic agents. Such formulations arepreferably adjusted to a pH and isotonic state compatible with the nasalmucous membranes.

Furthermore, co-administration or sequential administration of otheragents may be desirable. Preferably, the antibody is present in anamount sufficient to restore normal behavior and/or cognitive propertiesin case of Alzheimer's disease.

In a further embodiment, the present invention provides methods for thetreatment, prevention and/or delay of progression of a neurologicaldisease as mentioned above, comprising the step of administering aneffective amount of an antibody of the present invention to a subject inneed thereof.

Another object of the present invention is to provide a method forpassive immunization of a mammal, comprising the step of administeringthe antibody disclosed herein to a mammal. Preferably, the passiveimmunization is performed within the scope of an anti-Abetaimmunotherapy.

In another embodiment, the invention features isolated nucleic acidsequence comprising a sequence encoding the amino acid sequencesencompassed by the present invention. Said nucleic acids may be eitherDNA or RNA and be either single stranded or double stranded.

Furthermore, the present invention provides a cloning or expressionvector containing a DNA sequence coding for a polypeptide, mostpreferably the antibody, of the present invention.

In addition, a suitable host cell harbouring the vector and/or thenucleic acid sequence comprising a sequence coding for the heredisclosed amino acid sequences, is provided. This can be a prokaryoticor eukaryotic cell, in particular an E. coli, yeast, plant, insect or amammalian cell.

The antibody of the present invention may be generated using routinetechniques in the field of recombinant molecular biology. Knowing thesequences of the polypeptides, the person skilled in the art maygenerate corresponding cDNAs coding for the polypeptides by genesynthesis.

In another embodiment, a method for the production of the antibody ofthe present invention is provided, comprising culturing of the host celltransformed with the DNA encoding said antibody under conditions thatallow the synthesis of said antibody, and recovering said molecule fromsaid culture. Preferably, said method provides an scFv antibody purifiedfrom E. coli inclusion bodies or from the E. coli periplasm, if the scFvconstruct used comprises a signal sequence that directs the polypeptideto the periplasm. It may be necessary to include a renaturate step torefold the antibody to a functional molecule.

In a further embodiment, the invention provides a method of treatmentcomprising the step of administering to a subject in need thereof atherapeutically effective amount of a polynucleotide, vector or hostcell as described herein.

In a second aspect, the present invention provides a method of diagnosiscomprising the steps of:

(i) Labelling an antibody;

(ii) Administering an effective dose of said antibody intranasally orsystemically to a subject; and

(iii) Detecting the concentration and/or presence of the labelledantibody in body parts of the subject.

The antibody is preferably the humanized antibody against the epitopeformed within the amino acids 30 to 40 of Abeta of the presentinvention, preferably a single chain antibody (scFv). In a preferredembodiment, the antibody is labelled with a positron emitting isotope,most preferably ⁶⁴CU

The term “effective dose” as used herein refers to an amount sufficientto achieve or at least partially achieve the desired effect, e.g. adetectable signal. Amounts effective for this use will depend upon thedetective strength of the label, body mass of the subject and the extentof the area to be examined.

Preferably, the subject is a mammal; more preferably, the subject is ahuman being.

The medical imaging technique Positron emission tomography (PET) whichproduces a three-dimensional image of body parts is based on thedetection of radiation from the emission of positrons. Typically, abiomolecule is radioactively labeled, e.g. it incorporates a radioactivetracer isotope. Upon administration of the labeled biomolecule to thesubject, typically by injection into the blood circulation, theradioactively labeled biomolecule becomes concentrated in tissues ofinterest. The subject is then placed in the imaging scanner, whichdetects the emission of positrons.

In one embodiment, a ⁶⁴Cu labelled antibody is administered to a subjectand step iii) is performed by placing the subject in an imaging scannerand detecting the emission of positrons.

The invention thus encompasses a method for PET imagining, comprisingthe step of administering a ⁶⁴Cu-labelled antibody of the presentinvention to a subject.

The sequences of the present invention are the following:

SEQ. ID. No. 1: CDR1 of VL RASSSVNYMH SEQ. ID. No. 2: CDR2 of VL ATSNLASSEQ. ID. No. 3: CDR3 of VL QQWRTNPPT SEQ. ID. No. 4: CDR1 of VH EYTMHSEQ. ID. No. 5: CDR2 of VH GVNPYNDNTSYIRKLQG SEQ. ID. No. 6: CDR3 of VHYGGLRPYYFPMDF SEQ. ID. No. 7: VL of ESBA212ADIVLTQSPSSLSASVGDRVTLTCRASSSVNYMHWYQQRPGKPPKALIYATSNLASGVPSRFSGSGSGTEFTLTISSLQPEDVAVYYCQQWRTNP PTFGQGTKLEVKRSEQ. ID. No. 8: VL of Framework 2.3AEIVLTQSPSSLSASVGDRVTLTCRASQGIRNELAWYQQRPGKAPKRLIYAGSILQSGVPSFSGSGSGTEFTLTISSLQPEDVAVYYCQQYYSLP YMFGQGTKVDIKRSEQ. ID. No. 9: VL of 22C4 DIVLTQSPAILSASPGEKVTLTCRASSSVNYMHWYQQKPGSPPKAWIYATSNLASGVPDRFSASGSGTSYSLTISRVEAEDAATYYCQQWRTNPP TFGAGTKLELKRSEQ. ID. No. 10: VL A EIVMTQSPSTLSASVGDRVIITORASQSISSWLAWYQQKPGKAPKLLIYKASSLESG VPSRFSGSGSGAEFTLTISSLQPDDFATYYCQQYKSYWTFGQ GTKLTVLG;SEQ. ID. No. 11: VL B EIVLTQSPSSLSASVGDRVTLTCRASQGIRNELAWYQQRPGKAPKRLIYAGSILQSG VPSRFSGSGSGTEFTLTISSLQPEDVAVYYCQQYYSLPYMFG QGTKVDIKR;SEQ. ID. No. 12: VL C EIVMTQSPATLSVSPGESAALSCRASQGVSTNVAWYQQKPGQAPRLLIYGATTRASGVPARFSGSGSGTEFTLTINSLQSEDFAAYYCQQYKHWP PWTFGQG TKVEIKR;SEQ. ID. No. 13: VL D QSVLTQPPSVSAAPGQKVTISCSGSTSNIGDNYVSWYQQLPGTAPQLLIYDNTKRPS GI PDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSG VVFGGGTKLTVLG;SEQ. ID. No. 14: VL E EIVLTQSPATLSLSPGERATLSCRASQTLTHYLAWYQQKPGQAPRLLIYDTSKRATGVPARFSGSGSGTDFTLTISSLEPEDSALYYCQQRNSWP HTFGGGTKLEIKR;SEQ. ID. No. 15: VL F SYVLTQPPSVSVAPGQTATVTCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTIRRVEAGDEADYYCQVWDSSSD HNVFGSGTKVEIKR;SEQ. ID. No. 16: VL G LPVLTQPPSVSVAPGQTARISCGGNNIETISVHWYQQKPGQAPVLVVSDDSVRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSD YVVFGGGTKLTVLG;SEQ. ID. No. 17: VH of ESBA212QVQLVQSGPEVKKPGASVKVSCTASGYTFTEYTMHWVRQAPGQGLEWMGGVNPYNDNTSYIRKLQGRVTLTVDRSSSTAYMELTSLTSDDTAVYYCARYGGLRPYYFPMDFWGQGTLVTVSS SEQ. ID. No. 18: VH of Framework 2.3QVQLVQSGAEVKKPGASVKVSCTASGYSFTGYFLHWVRQAPGQGLEWMGRINPDSGDTYAQKFQDRVTLTRDTSIGTVYMELTSLTSDDTAVYYCARVPRGTYLDPWDYFDYWGQGTLVTVSS SEQ. ID. No. 19: VH of 22C4QVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGVNPYNDNTSYIRKLQGKVTLTVDRSSSTAYMELRSLTSEDSAVYFCARYGGLRPYYFPMDFWGQGTSVTVSS SEQ. ID. No. 20: VH HQVQLVQSGGGLVQPGGSLRLSCAASGFTESSYAMSWVRQAPGKGLEWVSAISGSGGS TYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAHVLRFLEWLPDAFDIW GQGTLVTVSS SEQ. ID. No. 21: VH IEIVLTQSPSSLSASLGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSSQSGVPSRFRGSESGTDFTLTISNLQPEDFATYYCQQSYRTP FTFGPGTKVEIKRSEQ. ID. No. 22: VH J VQLVQSGAEVKKPGASVKVSCTASGYSFTGYFLHWVRQAPGQGLEWMGRINPDSGDTIYAQKFQDRVTLTRDTSIGTVYMELTSLTSDDTAVYYCARVPRGTYLDPWDYFDYWGQGTLVTVSS SEQ. ID. No. 23: VH KEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDAGIAVAGTGFDYWGQGTLVTVSS SEQ. ID. No. 24: ESBA212 (The CDRsaccording to Kabat are underlined, andthe linker sequence is shown in italics).ADIVLTQSPSSLSASVGDRVTLTCRASSSVNYMHWYQQRPGKPPKALIYATSNLASGVPSRFSGSGSGTEFTLTISSLUEDVAVYYCQQWRTNPPTFGQGTKLEVKRGGGGSGGGGSGGGGSGGGGSQVQLVQSGPEVKKPGASVKVSCTASGYTFTEYTMHWVRQAPGQGLEWMGGVNPYNDNTSYIRKLQGRVTLTVDRSSSTAYMELTSLTSDDTAVYYCARYGGLRPYYFPMDFWGQGTLV TVSSSEQ. ID. No. 25: linker GGGGSGGGGSGGGGSGGGGSSEQ. ID. No. 26: Abeta₃₀₋₄₀ epitope AIIGLMVGGVV

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. In case of conflict, the presentspecification, including definitions, will control.

In addition, the materials, methods, and examples are illustrative onlyand not intended to be limiting.

It is understood that the various embodiments, preferences and rangesmay be combined at will. Further, depending of the specific embodiment,selected definitions, embodiments or ranges may not apply.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be better understood and objects other than those setforth above will become apparent when consideration is given to thefollowing detailed description thereof. Such description makes referenceto the annexed drawings, wherein:

FIG. 1 shows a sequence comparison of the light chain variable region ofESBA212 (SEQ ID NO: 7) with the VL of ESBATech's framework 2.3 (SEQ IDNO: 8) onto which the Abeta specific CDRs from 22C4 were grafted.

In FIG. 2, a sequence comparison of the variable heavy chain VH ofESBA212 (SEQ ID NO: 17) with the VH of ESBATech's framework 2.3 (SEQ IDNO: 18) is illustrated.

FIG. 3 depicts a sequence alignment of VH of ESBA212 (SEQ ID NO: 17)with the VH of the original VH from the mouse 22C4 antibody (SEQ ID NO:19).

FIG. 4: shows a sequence alignment of the VH of ESBA212 (SEQ ID NO: 17),22C4 (SEQ ID NO: 19) and framework (SEQ ID NO: 18).

FIG. 5. shows the results of ex vivo labeling of plaques in AD mousemodels by ESBA212. Either paraffin sections or cryosections (non-fixedand post-fixed) were used. FIG. 5A: mouse model SwePS1, paraffinsection; FIG. 5B: mouse model SwePS1, cryo section; FIG. 5C: mouse modelSweArc, paraffin section; FIG. 5D: mouse model SweArc, cryo section.

FIG. 6. depicts the results of ex vivo labeling of plaques in human ADbrains by ESBA212. Either paraffin sections or cryosections (non-fixedand post-fixed) were used FIG. 6A: Paraffin section; FIG. 6B: cryo,acetone fixed; FIG. 6C: cryo, untreated; FIG. 6D: cryo; acetone fixed,boiled for 10 min in citrate buffer.

FIG. 7. shows the ex vivo staining of amyloid plaques by ESBA212 (FIG.7A) and Thioflavine S (FIG. 7B) on brain sections of SwePS1 mice.

FIG. 8: illustrates the results of size exclusion chromatography ofESBA212 bound to FITC labeled Abeta42 monomers (FIG. 8A) and in FIG. 8Ba control wherein the framework FW2.3 was incubated with FITC labeledAbeta42 monomers.

FIG. 9. shows two Abeta42 immunoblots using brain homogenates oftransgenic SwePS1 mice (FIG. 9A; lane 1: ESBA212, lane 2: 6E10) andADDLs (FIG. 9B; lane 1: Fw 2.3, lane 2: ESBA212, lane 3: 6E10) asantigens. ESBA212 recognizes predominantly monomers and weaker trimers.

FIG. 10: Determination of affinity of ESBA212 by ELISA (FIG. 10A: forAbeta40; affinity constant: 6.26 nM; and FIG. 10B for Abeta42; affinityconstant: 6.31 nM).

FIG. 11: Mass spectroscopy of ESBA212.

FIG. 12 depicts a FT-IR spectrum, showing the 5 percentage unfolding ofESBA212 at different temperatures, ranging from 25 to 95° C.

FIG. 13: Western blot showing the stability of ESBA212 incubated in thepresence (lane 1) or absence (lane 2) of mouse brain homogenate.

FIG. 14: Result of a thioflavine T assay demonstrating that ESBA212inhibits Abeta42 oligmerisation in vitro.

FIG. 15: Mean serum concentrations of ESBA212 over time after a singleintravenous or intraperitoneal injection.

FIG. 16: Detection of bound ESBA212 after intranasal (FIG. 16A) orintravenous (FIG. 16B) application. ESBA212 binds to amyloid plaques inthe brain independent of the chosen route of application.

FIG. 17: Detection of bound ESBA212 in SwePS1 mouse brains afterintranasal application (FIG. 17A) and thioflavine S staining (FIG. 17B)confirming that ESBA212 binds to amyloid plaques.

FIG. 18: Ex vivo labelling of amyloid plaques by ⁶⁴Cu-ESBA212 (FIGS. 18Band D) compared to ESBA212 (FIGS. 18A and C). FIGS. 18A and B showparaffin sections, whereas FIGS. 18 C and D show cryo sections.

FIG. 19: Detection of bound ESBA212 and Cu-ESBA212 on mouse (SwePS1)brain sections 24 hours and 48 hours after intranasal application. FIG.19A: ESBA212 after 24 h; FIG. 19B: ESBA212 after 48 h; FIG. 19C:Cu-ESBA212 after 24 h; and FIG. 19D: Cu-ESBA212 after 48 h.

FIG. 20: Detection of ESBA212 in the kidney following an intravenousESBA212 injection.

FIG. 21(A-D): Further intranasal application similar to FIG. 16A showingAβ-staining on fixed SwePS1 mouse brain slices of an animal perfused 1 hafter intranasal treatment with 200 pg of ESBA212. Brain slices werestained with anti-His antibody (FIG. 21A), 6E10 control antibody (FIG.21B), anti-rabbit Cy3 negative control antibody (FIG. 21C), or 22c4 IgGcontrol antibody (FIG. 21D).

FIG. 22(A-C): Brain Aβ 40 and 42 levels in APPswe/PS1AE9 mice treatedwith PBS, 22c4 IgG and ESBA212 for 3 months. The soluble fraction (TBS),the insoluble fraction (GuHCl), and the membrane-bound fraction(TBS-Triton) are depicted in FIG. 22A, FIG. 22B, and FIG. 22C,respectively.

FIG. 23(A-B): Paraffin sections of treated APPswe/PS1AE9 mice stainedwith 6E10 and evaluated using ImageJ software. The plaque number (FIG.23A) and plaque area (FIG. 23B) are shown.

MODES FOR CARRYING OUT THE INVENTION Example 1 Generation of ESBA212

The antigen-binding portions of the single chain antibody ESBA212emanate from the murine antibody 22C4, identified by the University ofZurich. The Abeta-specific mouse IgG antibody 22C4 was generated byimmunizing mice with Abeta₃₀₋₄₂ and is thus directed against theC-terminus of Abeta. The cloning of the VL and the VH domains was doneby RT-PCR according to Burmester and PlUckthun (2001). Briefly, the mRNAwas derived from hybridoma cells producing the antibody 22C4. An RT-PCRusing the primers described by Burmester and Pluckthun was performed toamplify the VL and VH domains. The two domains were assembled by aSOE-PCR (splicing by overlap extension). Then the amplified single chainvariable fragment (scFv) was digested by SfiI, cloned into a suitableexpression vector and sequenced. Thus a mouse scFv fragment was obtainedwhich kept its specificity for Abeta₄₂. Said scFv was humanized leadingto the single chain antibody ESBA212 (see FIGS. 1 to 4 for sequencecomparisions. FIGS. 1 and 2 show a sequence alignment of ESBA212 withthe framework 2.3 onto which the Abeta specific CDRs from 22C4 weregrafted).

Plasmids encoding ESBA212 were introduced into a suitable E. coli strain(e.g. BL21) and expressed 10 as inclusion bodies. Functional singlechain antibodies were obtained by refolding of inclusion bodies andsubsequent purification by gel filtration.

Example 2 Binding to Amyloid Plaques on Tissue Sections

In order to test whether the scFv ESBA212 was able to recognise Abeta,ex vivo immunostainings of brain tissues containing amyloid plaques wereperformed. Therefore, brain tissue sections from various transgenic mice(SweArc, SwePS1) that express human APP leading to the formation ofAbeta plaques and brain sections from human Alzheimer's patients wereused.

ESBA212 reacted with amyloid plaques on both 25 cryo and paraffinsections from mice independent of the Alzheimer's mouse model used (FIG.5). ESBA212 also stained plaques on fixed human Alzheimer's tissue (FIG.6A). Especially around the vessels a strong staining could be observedthat is known as amyloid angiopathy. Amyloid angiopathy refers to thedeposition of beta-amyloid in the small and mid-sized vessels of thecerebral cortex and the leptomeninges. However, ESBA212 does not bind toamyloid plaques on human cryo sections, neither on non-fixed (FIG. 6B)nor on post-fixed (FIG. 356C, D) sections.

The different results between the human and rodent sections may beexplained in that transgenic mice overexpress human APP and thereforethe abundance of different plaques species might be different comparedto humans. Güntert et al. (2006) described that there is anultrastructural difference between diffuse plaques in a transgenic mousemodel and human AD brains. In the mouse brain compact plaques ofdifferent sizes represent the majority. In the cortex and thehippocampus of human AD patients this plaque type occurs at only 10%,whereas cored plaques predominate (−90%) (Gantert et al., 2006). Becauseof these observed differences the C-terminus might be accessible inbrains of transgenic mice but not In brains of AD patients. The fixationof human brain tissue might alter the conformation of the amyloidplaques in a way that the otherwise buried C-terminal epitope is exposedand gets accessible for ESBA212.

FIG. 7 shows the specific binding of ESBA212 to amyloid plaques onSwePS1 brain sections as the staining pattern of ESBA212 coincided withthe pattern of thioflavine S which is a standard fluorescent stain thatspecifically binds to amyloid protein deposits.

Example 3 Binding to Abeta42 Monomers

It could be shown by size exclusion chromatography that ESBA212 bound toFITC-labelled Abeta 42. ESBA212 was co-incubated with FITC-Abeta42 andloaded onto a column. ESBA212 and FITC-Abeta42 were eluted together(FIG. 8A) as the peak for ESBA212 and the one for FITC-Abeta42overlapped exactly and also showed a size shift of 5 kDa compared toESBA212 alone (data not shown), therefore representing boundFITC-Abeta42 (5 kDa). However, when FITC-Abeta42 was incubated with theframework FW2.3, which contains the same framework region as ESBA212 butno Abeta-specific CDRs, there were two clearly distinct peaks observedone for the scFv and a second one for FITC-Abeta42 (FIG. 8B).

Example 4 Binding to Different Abeta42 Conformations

Abeta42 immunoblots were performed to further characterize thespecificity of ESBA212. Therefore, brain homogenates of SwePS1 mice aswell as in vitro generated ADDLs (amyloid beta-derived diffusibleligands, protocol by Klein) were separated on a SDS gel and transferredto a membrane. ESBA212 and 6E10 (Abeta-specific IgG as control) wereused to detect Abeta. The control antibody 6E10 recognised Abeta42monomers, beta-stubs, trimers and also full-length APP. However, ESBA212recognised predominantly Abeta42 monomers (FIG. 9).

Example 5 In Vitro Characterization of Affinity

The binding properties of ESBA212 were tested in an ELISA where Abeta40and Abeta42, respectively, were used as antigens. 96-well plates werecoated with 5 ug/ml neutravidin in dilution buffer (PBS/0.01% BSA/0.2%Tween-20) and incubated overnight at 4° C. The plates were then washed 3times with TBS/0.005% Tween-20. Biotinylated Abeta40 or Abeta42 (1 ug/mlin dilution buffer) were added to each well and the plate incubated for15 minutes at room temperature. Plates were washed as above andnon-specific binding sites were blocked by addition of dilution buffer.The plates were incubated for another 1.5 hours at room temperaturewhile shaking. After washing the prepared ESBA212 dilutions from 0 to500 nM were added in triplicates to the wells and incubated for 1 hourat room temperature (RT) while shaking. Plates were washed and ESBA212was detected by a purified rabbit polyclonal anti-ESBA212 antibody(1:10000 in dilution buffer) for 1 hour at RT. After washing ahorseradish peroxidase-labelled anti-rabbit IgG (1:4000 in dilutionbuffer) was used to detect the previously bound rabbit antibodies andPOD was used as substrate. The reaction was stopped by addition of 1 MHCl and the absorption read at 450 nm.

From the measured ESBA212 curve an EC50 could be calculated. For ESBA212the EC50 was determined to be in the range of 1-15 nM for Abeta40 aswell as for Abeta42 (FIG. 10).

Example 6 Mass Determination

The exact mass of ESBA212 was determined by electrospray massspectroscopy. Therefore, ESBA212 was purified and measured in 50%acetonitrile/0.2% formic acid (pH2). Mass spectra (neutral mass) weredeconvoluted using the MaxEntl software.

The mass of ESBA212 was determined to be 26517 Da (FIG. 11).

Example 7 Determination of Solubility by PEG-Precipitation

The apparent solubility of ESBA212 was measured in the presence ofpolyethylene glycol 3000 (PEG3000) according to the method of Atha andIngham (1981). ESBA212 (20 mg/ml) was incubated with equal volumes ofbuffer containing different concentrations of PEG3000 (30-50%) resultingin a final protein concentration of 10 mg/ml and a final PEGconcentration of 15-25%. After 30 minutes of incubation at roomtemperature the samples were centrifuged and the protein concentrationin the supernatant determined from the absorbance at 280 nm. Theapparent solubility was calculated by plotting the PEG concentrationagainst the logarithm of the protein concentration measured in thesupernatant. The solubility was determined by extrapolation to 0% PEG.

The solubility of ESBA212 was determined to be about 20 mg/ml.

Example 8 Determination of Thermal Stability

The thermal stability of ESBA212 was determined by measuring the Fouriertransform-infrared (FT-IR) spectrum on a Bruker Tensor 27 spectrometeras the temperature is increased from 25-95° C. ESBA212 was left toequilibrate at each temperature for 1-2 minutes before the spectrum wasmeasured.

The melting temperature of ESBA212 (50% unfolding of the protein) wasdetermined to be at 62.8° C. However, the unfolding of ESBA212 startsalready at about 40° C. (FIG. 12).

Example 9 Prevention of Abeta Aggregation In Vitro

It was investigated whether ESBA212 was able to inhibit the formation ofAbeta42 oligomerisation. Therefore, a thioflavine T assay was performedin solution. Thioflavine T associates rapidly with aggregated Abetafibrils, giving rise to enhanced emission at 482 nm as opposed to the445 nm of the free dye. This change is dependent on the aggregated stateof Abeta as monomeric or dimeric peptides do not react (LeVine III,1993).

2.5 μM Abeta42 were incubated with or without 2.27 μM ESBA212 in thepresence of thioflavine T and 500 mM NaCl. As can be seen in FIG. 14 thepresence of ESBA212 clearly inhibits the Abeta oligomerisation in vitroover 3 hours as the fluorescence measured at 482 nm does not rise. Incontrast, when no ESBA212 was added to the solution higher values offluorescence were measured indicating the formation of Abeta aggregates.

Example 10 In Vivo Characterization of Pharmacokinetic Properties

In order to determine the pharmacokinetic properties of ESBA212,APP-transgenic mice as well as non-transgenic littermates were treatedintravenously or intraperitoneally with a single injection of ESBA212.At predefined time points after the injection blood was drawnretro-orbitally, the amount of ESBA212 in the serum measured byquantitative ELISA and the data analysed using the PK-Summit software.

Animals: For the pharmacokinetic experiments an Alzheimer mouse modelwas used that was generated by Prof. Dr. R. Nitsch (University ofZurich). These mice (PrP-APP Sw/Arc 10+) over-express the human APP695containing both the Swedish and the Arctic mutation in a singleconstruct under the control of the prion protein promoter (Knobloch etal, 2006). The mice were bred on the hybrid background of C57BL/6 andDBA/2 preventing the occurrence of health and breeding problems. Thecharacteristics of this strain are: i) the formation of earlyintracellular Abeta deposits that is associated with impaired cognitivefunctions from the age of 6 month; ii) the formation of plaques startingat the age of 7 month and highly increasing over the next few month.This development of beta-amyloid plaques coincides with severe cerebralamyloid angiopathy (CAA) (Knobloch et al. 2006).

The mice used for the pharmacokinetic studies 30 were at the age of 6month.

Experimental procedure: The pharmacokinetic parameters were determinedafter intravenous or intraperitoneal injection of ESBA212. In case ofthe intravenous treatment APP-transgenic mice and non-transgeniclittermates were used. 7 groups of 2 animals received a singleintravenous injection of 15 mg/kg ESBA212 in PBS, pH 6.5. Blood wasdrawn retro-orbitally at predefined time points (10 and 30 minutes, 1,2, 4, 8, 12, and 24 h) in a way that 4 samples per time point could becollected (exception: only 2 samples at 10 min and 24 h). ESBA212concentrations in the serum were measured by a quantitative ELISA.

In case of the intraperitoneal application of ESBA212, onlyAPP-transgenic mice were used. 7 groups of 2 animals received a singleintraperitoneal injection of 20 mg/kg ESBA212 in PBS, pH 6.5. Bloodsamples were collected as described above for the intravenous treatment.

Results: After intravenous injection of ESBA212 the systemic PK followeda bi-phasic clearance. Upon injection there was a clear distributionphase (B-elimination, 0-1 h) as well as a terminal elimination phase(α-elimination, 8-12 h) observed (FIG. 15). There was no significantdifference in the a-elimination (0.26 versus 0.23 h) and terminalhalf-life (8.79 versus 7.11 h) in the transgenic and non-transgenicmice, respectively (Table 1). Also the other calculated PK-values werecomparable in the transgenic and non-transgenic mice. However, theobserved volume of distribution (Vd) is quite high (77.69 and 76.72 ml).This might hint that ESBA212 penetrates very well and quickly into thetissue. In contrast, there were differences observed in thepharmacokinetics when ESBA212 was applied intraperitoneally. A clearabsorption phase could be detected with a peak ESBA212 serumconcentration at 1 hour after the injection. Then the distributionhalf-life was about 5 times longer than after intravenous applicationwhich might give an indication that a depot effect was obtained wheninjected via the intraperitoneal route. However, the calculated terminalhalf-life was slightly shorter after intraperitoneal than intravenousinjection. A clear difference was also detected in the mean residencetime (MRT) of ESBA212 in the organism, which was about 3 times longerwhen the scFv was injected intraperitoneally instead of intravenously.The observed differences in the AUC (area under curve), Volume ofdistribution (Vd) and clearance (CL) between the intravenous andintraperitoneal route of injection could be explained by the fact thatthe animals treated intraperitoneally received a higher dose of ESBA212(20 mg/kg instead of 15 mg/kg). When calculating the PK-parameters foran intraperitoneal dose of 15 mg/kg based on the values obtained for 20mg/kg the following parameters were obtained: no changes in absorption,distribution and elimination half-life as well as in the MRT. However,the AUC (79.124 ug-h/ml), Vd (67.52 ml) and CL (7.84 ml/h) were thencomparable to the values obtained after intravenous injection.

TABLE 1 Pharmacokinetic parameters after intravenous and intraperitonealinjection of ESBA212. PrP-APP PrP-APP PrP-APP Sw/Arc Sw/Arc Sw/Arc (tg)(non-tg) (tg) route of application i.v. i.v. i.p. dosage mg/kg 15 15 20absorption half-life h 0.10 distribution half-life h 0.26 0.23 1.28elimination half-life h 8.79 7.11 5.84 area under curve (AUC) μg-h/ml80.663 66.292 105.491 mean residence time h 1.23 1.72 4.32 (MRT) volumeof distribution ml 77.69 76.72 50.62 (Vd) clearance (CL) ml/h 6.06 7.385.88

Example 11 In Vivo Plaque Labelling

It was investigated whether ESBA212 was able 5 to bind to amyloidplaques when applied intravenously or intranasally.

Therefore, transgenic SwePS1 mice were treated 3 times every 24 h with210 μg of ESBA212 either by the intravenous or intranasal route ofapplication. 72 h after the first application the animals were perfusedwith PBS and the brains analysed for the presence of ESBA212. ESBA212bound to amyloid plaques in the brain both after intravenous andintranasal application of the scFv (FIG. 16). A thioflavine S stainingconfirmed that ESBA212 really bound to amyloid plaques. Consecutivebrain sections of a SwePS1 mouse that was treated intranasally withESBA212 showed the same staining pattern for ESBA212 and thioflavine S(FIG. 17).

Example 12 PET-Imaging with ⁶⁴Cu-Labelled ESBA212

⁶⁴Cu-labelling of ESBA212: ESBA212 was coupled to a CPTA chelator (anapproximately 200 Da macrocycle with 4 N-atoms) which binds to theisotope (half-life of 64Cu is 12.7 hours). The chelator was coupled tolysine residues within the ESBA212. As the coupling was mild not everylysine was labelled. It was shown by mass determination that on averagetwo CPTA molecules were bound to each ESBA212 molecule.

Example 13 Ex Vivo Labelling of Plaques by ⁶⁴Cu-ESBA212

In order to define whether 64Cu-ESBA212 was still able to bind toamyloid plaques, immunohistochemical stainings on fixed and non-fixedSwePS1 mouse brain sections were performed. The ⁶⁴Cu-labelling did notchange the binding properties of ESBA212 as ⁶⁴Cu-ESBA212 was still ableto bind to amyloid plaques on fixed as well as non-fixed brain sections(FIG. 18).

Example 14 In Vivo Labelling of Plaques by ⁶⁴Cu-ESBA212

The binding properties of coldly labelled Cu-ESBA212 were investigatedin vivo using transgenic SwePS1 mice. The mice received an intranasalapplication of either 210 ug ESBA212 or 100 ug Cu-ESBA212. The animalswere sacrificed 24 or 48 hours after the application and the brains wereanalysed for the binding of ESBA212 and Cu-ESBA212, respectively, toamyloid plaques.

As seen in FIG. 19, ESBA212 could be detected after 24 as well as 48hours post application. The same result was observed for the Cu-labelledESBA212. Therefore, the binding properties of Cu-ESBA212 did not changein vivo compared to ESBA212 as it was already demonstrated for the exvivo labelling.

Example 15 Elimination via kidney

In order to get some information about the elimination pathway ofESBA212 the scFv was injected intravenously into mice. Animals weresacrificed shortly afterwards and the kidneys analysed byimmunohistochemical methods.

ESBA212 is filtered into the primary urine in the kidney and reabsorbedin the proximal tubulus where it is degraded most probably via thelysosomal pathway (FIG. 20).

Example 16 In Vivo Plaque Labelling

A further test similar to the test performed in Example 11 was made withintranasal administration.

Transgenic SwePS1 mice were treated intranasally with 200 μg of ESBA212.The animal was perfused 1 h after intranasal treatment. AB-staining onfixed SwePS1 mouse brain slices was performed and recorded as follows:

Stained with anti-His antibody (FIG. 21A)

Control stained with 6E10 (FIG. 21B)

Negative control stained with anti-rabbit Cy3 (FIG. 21C)

Control stained with 22c4 IgG (FIG. 21D)

Example 17

APPswe/PS1ΔE9 mice were treated for 3 months with PBS, 22c4 IgG once aweek each and with ESBA212 twice a week. At the end of the treatment theanimals were perfused, the brain was isolated and divided into twoportions. One portion was homogenized and several extracts were producedand the brain Aβ 40 and 42 levels were determined using a commercialELISA test (The Genetics Company). It was found that the Aβ 40 and 42levels were increased in the soluble fraction (TBS) and decreased in theinsoluble fraction (GuHCl). In the membrane-bound fraction (TBS-Triton)the Aβ 40 level remained unchanged whereas the Aβ 42 level was increased(see FIG. 22). This points to a redistribution of Aβ from the insolubleto the soluble fraction.

The other portion was used for histology. Paraffin sections of treatedAPPswe/PS1LE9 mice were stained with 6E10. Plaque number and area wasevaluated using ImageJ software.

The experiment revealed that animals treated with ESBA212 show asignificantly reduced number and also a decreased size ofamyloid-plaques (see FIG. 23). This further supports the idea thatESBA212 binds to Aβ fibrils and subsequently breaks them up intomonomers or small oligomers, which shifts the equilibrium towardssoluble Aβ pools.

The above shown results support the finding that ESBA212 enters thebrain after intravenous and intranasal application, and binds to Abetaplaques in the cortex and hippocampus of transgenic mice. Moreover,APPswe/PS1ΔE9 mice treated intranasally with scFv exhibited reducednumber and average size of amyloid plaques in the cortex, as well asreduced levels of Aβ42 in the insoluble fraction of brain extracts.

While there are shown and described presently preferred embodiments ofthe invention, it is to be distinctly understood that the invention isnot limited thereto but may be otherwise variously embodied andpractised within the scope of the following claims.

REFERENCES

-   Alfthan et al. (1995) Protein Eng. 8:725-731.-   Altschul et al., (1997) Nucleic Acids Res. 25(17):3389L-3402.-   Altschul, S. F., Gish, W., Miller, W., Myers, E. W. &    Lipman, D. J. (1990) “Basic local alignment search tool.” J. Mol.    Biol. 215:403-410.-   Atha, Donald H. and Ingham, Kenneth C. (1981): Mechanism of    precipitation of proteins by polyethylene glycols, JBC 256:    12108-12117.-   Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games,    D., Seubert, P., Schenk, D. and Hyman, B. T. (2001): Imaging of    amyloid-beta deposits in brains of living mice permits direct    observation of clearance of plaques with immunotherapy. Nat. Med. 7,    369-372.-   Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert,    P., Schenk, D. and Hyman, B. T. (2002): Non-Fcmediated mechanisms    are involved in clearance of amyloid-beta in vivo by    immunotherapy. J. Neurosci. 22, 7873-7878.-   Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda,    H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K.,    Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M.,    Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P.,    Schenk, D. and Yednock, T. (2000): Peripherally administered    antibodies against amyloid beta-peptide enter the central nervous    system and reduce pathology in a mouse model of Alzheimer disease.    Nat. Med. 6, 916-919.-   Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007):    Forecasting the global burden of Alzheimer's disease. Alzheimer's &    Dementia: The Journal of the Alzheimer's Association (Vol. 3 (3)).-   Burmester, J. and PliAckthun, A. (2001): Construction of scFv    fragments from hybridoma or spleen cells by PCR assembly, in:    Antibody Engineering, R. Kontermann and S. Dtbel, Eds.,    Springer-Verlag, Berlin Heidelberg, pp. 19-40.-   Chothia, C., and Lesk, A. M. (1987). Canonical structures for the    hypervariable regions of immunoglobulins. J Mol Biol 196, 901-917.-   Davies, D. R. et al., “Antibody-Antigen Complexes” Ann. Rev.    Biochem. 59:439-473 (1990).-   DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C.,    Paul, S. M. and Holtzman, D. M. (2001): Peripheral anti-Abeta    antibody alters CNS and plasma Abeta clearance and decreases brain    Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl.    Acad. Sci. USA 98, 8850-8855.-   Frenkel, D., Katz, O. and Solomon, B. (2000): Immunization against    Alzheimer's beta-amyloid plaques via EFRH phage administration.    Proc. Natl. Acad. Sci. USA 97, 11455-11459.-   Gaugler, M., Tracy, J., Kuhnle, K., Crameri, A., Nitsch, R. M. and    Mohajeri, M. H. (2005): Modulation of Alzheimer's pathology by    cerebro-ventricular grafting of hybridoma cells expressing    antibodies against Abeta in vivo. FEBS Letters 579, pp. 753-756.-   Giintert, A., Dobeli, H. and Bohrmann, B. (2006): High sensitivity    analysis of amyloid-beta peptide composition in anyloid deposits    from human and PS2APP mouse brain. Neuroscience 143: 461-475.-   Holliger, P. and Hudson, P. (2005), Nat. Biotechnol. 23(9), pp.    1126-1136.-   Kabat E A, Wu T T, Perry H M, Gottesman K S, Foeller C. 1991.    Sequences of proteins of immunological interest. 5th ed. Bethesda,    Md.: National Institutes of Health.-   Klein, W. L. (2002): Ab toxicity in Alzheimer's disease: globular    oligomers (ADDLs) as new vaccine and drug targets. Neurochemistry    International 41: 345-352-   Knobloch, M., Konietzko, U., Krebs, D. C., and Nitsch, R. M. (2006):    Intracellular Abeta and cognitive deficits precede beta-amyloid    deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007    September; 28(9):1297-306. Epub 2006 Jul. 31.-   LeVine III, H. (1993): Thioflavine T interaction with synthetic    Alzheimer's disease beta-amyloid peptides: Detection of amyloid    aggregation in solution. Protein Science 2: 404-410.-   Miller, R. et al. (1983): Monoclonal antibody therapeutic trials in    seven patients with T-cell lymphoma. Blood 62:988-995.-   Mohajeri, M. H., Gaugler, M., Martinez, J., Tracy, J., Li, H.,    Crameri, A., Kuehnle, K., Wollmer, Am. A. and Nitsch, R. M. (2004):    Assessment of the bioactivity of Antibodies against beta-amyloid    peptide in vitro and in vivo. Neurodegenerative dis. 1, pp. 160-167.-   Schroff, R. et al. (1985): Human anti-murine immunoglobulin    responses in patients receiving monoclonal antibody therapy. Cancer    Research 45:879-885.-   Worn A, Auf der Maur A, Escher D, Honegger A, Barberis A,    Pluckthun A. (2000): Correlation between in vitro stability and in    vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors.    J Biol. Chem. 275(4):2795-803.

1.-74. (canceled)
 75. A nucleic acid sequence encoding an antibodycomprising the variable light fragment (VL) sequence set forth in SEQ IDNO: 7 and the variable heavy chain fragment (VH) sequence set forth inSEQ ID NO:
 17. 76. A nucleic acid sequence encoding an antibody thatselectively binds to the C-terminal part of beta-amyloid, the antibodycomprising a variable light chain fragment (VL) sequence comprising thevariable light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ IDNos: 1, 2 and 3, respectively, and a variable heavy chain fragment (VH)sequence comprising the variable heavy chain CDR1, CDR2 and CDR3sequences set forth in SEQ ID Nos: 4, 5, and 6, respectively, wherein a)position 1 of the light chain is an aspartate residue; b) position 43 ofthe light chain is a proline residue; c) position 46 of the light chainis an alanine residue; d) position 61 of the light chain is an arginineresidue; e) position 104 of the light chain is leucine residue; f)position 105 of the light chain is a glutamate residue; and g) position106 of the light chain is a valine residue, according to Kabatnumbering.
 77. The nucleic acid sequence of claim 76, wherein: a.position 9 of the heavy chain is a proline residue; b. position 28 ofthe heavy chain is a threonine residue; c. position 71 of the heavychain is a valine residue; d. position 73 of the heavy chain is aarginine residue; e. position 75 of the heavy chain is a serine residue;f. position 76 of the heavy chain is a serine residue; and g. position78 of the heavy chain is an alanine residue.
 78. The nucleic acidsequence of claim 76, wherein the antibody comprises the variable lightfragment (VL) sequence set forth in SEQ ID NO:
 7. 79. The nucleic acidsequence of claim 77, wherein the antibody comprises the variable heavychain fragment (VH) sequence set forth in SEQ ID NO:
 17. 80. The nucleicacid sequence of claim 75 or 76 encoding an antibody comprising SEQ IDNo:
 24. 81. A vector comprising the nucleic acid sequence of any one ofclaims 75-80.
 82. A host cell comprising the nucleic acid sequence ofany one of claims 75-80 or the vector of claim
 81. 83. A method oftreatment comprising the step of administering to a subject in needthereof a therapeutically effective amount of the nucleic acid sequenceof any one of claims 75-80, the vector of claim 81 or the host cell ofclaim 82.